GPCR (Structure Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GPCR Structure Therapeutics Inc GPCR
32 GF Score
Price $50.80
View Full Analysis

What is Structure Therapeutics FCF Margin %?

Structure Therapeutics GPCR +0.70% 32 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates GPCR with a GF Score™ of 32/100. Among 950 Biotechnology companies, Structure Therapeutics ranks worse than 105263.05% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Structure Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $14.05 Mil. Structure Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Structure Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Structure Therapeutics's current FCF Yield % is -4.41%.

The historical rank and industry rank for Structure Therapeutics's FCF Margin % or its related term are showing as below:


GPCR's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -79.025
* Ranked among companies with meaningful FCF Margin % only.

Structure Therapeutics FCF Margin % Related Terms

Structure Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Structure Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Structure Therapeutics FCF Margin % Chart

Structure Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Structure Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GPCR vs PBLS, IDYA, ELVN: FCF Margin % Comparison

For the Biotechnology subindustry, Structure Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Structure Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Structure Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Structure Therapeutics's FCF Margin % falls into.


GPCR
32GF Score
Structure Therapeutics Inc GPCR
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Structure Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Structure Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-225.813/0
= %

Structure Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=14.052/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Structure Therapeutics (GPCR) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Structure Therapeutics and its competitors. According to the industry distribution chart, Structure Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry.
Is Structure Therapeutics' FCF Margin % too high?
Structure Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Structure Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Structure Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Structure Therapeutics' FCF Margin % compare to PBLS and IDYA?
According to the Biotechnology industry distribution chart, Structure Therapeutics ranks #999999 out of 950 companies for FCF Margin %. This places Structure Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Structure Therapeutics and its competitors. Structure Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Structure Therapeutics stock overvalued right now?
Structure Therapeutics (GPCR) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Structure Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Structure Therapeutics (GPCR), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Structure Therapeutics Business Description

Address 601 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
32GF Score

Get the complete analysis for GPCR

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.80
Price